Cargando…
S100A7, a Novel Alzheimer's Disease Biomarker with Non-Amyloidogenic α-Secretase Activity Acts via Selective Promotion of ADAM-10
Alzheimer's disease (AD) is the most common cause of dementia among older people. At present, there is no cure for the disease and as of now there are no early diagnostic tests for AD. There is an urgency to develop a novel promising biomarker for early diagnosis of AD. Using surface-enhanced l...
Autores principales: | Qin, Weiping, Ho, Lap, Wang, Jun, Peskind, Elaine, Pasinetti, Giulio Maria |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613557/ https://www.ncbi.nlm.nih.gov/pubmed/19159013 http://dx.doi.org/10.1371/journal.pone.0004183 |
Ejemplares similares
-
α-Secretase nonsense mutation (ADAM10 Tyr167*) in familial Alzheimer’s disease
por: Agüero, Pablo, et al.
Publicado: (2020) -
Effect of Different Phospholipids on α-Secretase Activity in the Non-Amyloidogenic Pathway of Alzheimer’s Disease
por: Grimm, Marcus O. W., et al.
Publicado: (2013) -
Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer’s Disease Treatment
por: Peron, Rafaela, et al.
Publicado: (2018) -
The Polyherbal Wattana Formula Displays Anti-Amyloidogenic Properties by Increasing α-Secretase Activities
por: Htoo, Htut Htut, et al.
Publicado: (2017) -
The transmembrane domain of the amyloid precursor protein is required for antiamyloidogenic processing by α-secretase ADAM10
por: Hitschler, Lisa, et al.
Publicado: (2022)